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This study investigated the frequency of antimicrobial non-susceptibility (defined as the
frequency of isolates with minimum inhibitory concentrations above the CLSI susceptible
clinical breakpoint) among E. coli and Salmonella spp. isolated from healthy Australian
finisher pigs. E. coli (n = 201) and Salmonella spp. (n = 69) were isolated from cecal
contents of slaughter-age pigs, originating from 19 farms distributed throughout Australia
during July-December 2015. Isolates underwent minimum inhibitory concentration (MIC)
susceptibility testing to 11 antimicrobials. The highest frequencies of non-susceptibility
among respective isolates of E. coli and Salmonella spp. were to ampicillin (60.2
and 20.3%), tetracycline (68.2 and 26.1%), chloramphenicol (47.8 and 7.3%), and
trimethoprim/sulfamethoxazole (33.8 and 11.6%). Four E. coli isolates had MICs above
the wild-type epidemiological cut-off value for ciprofloxacin, with two isolates from the
same farm classified as clinically resistant (MICs of > 4µg/ml), a noteworthy finding given
that fluoroquinolones (FQs) are not legally available for use in Australian food-producing
animals. Three of these four E. coli isolates belonged to the sequence type (ST) 10, which
has been isolated from both humans and production animals, whilst one isolate belonged
to a new ST (7573) and possessed qnrS1. This study shows that non-susceptibility
to first line antimicrobials is common among E. coli and Salmonella spp. isolates from
healthy slaughter age pigs in Australia. However, very low levels of non-susceptibility
to critically important antimicrobials (CIAs), namely third generation cephalosporins and
fluoroquinolones were observed. Nevertheless, the isolation of two ciprofloxacin-resistant
E. coli isolates from Australian pigs demonstrates that even in the absence of local
antimicrobial selection pressure, fluoroquinolone-resistant E. coli clonal lineages may
enter livestock production facilities despite strict biosecurity.
Keywords: antimicrobial resistance, Escherichia coli, food-producing animals, fluoroquinolones, critically
important antimicrobials
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INTRODUCTION
Escherichia coli and Salmonella spp. while common commensals
in many animals, are also known to be the causative agents of
a number of production limiting diseases in pigs (Quinn et al.,
2011). E. coli can cause pre-weaning scours and septicemia in
piglets, post-weaning diarrhea and edema disease in weaners,
and mastitis and cystitis in sows (Zimmerman et al., 2012).
Enterotoxigenic E. coli (ETEC), the main agent associated
with post-weaning enteric colibacillosis, is among the most
significant bacterial pathogens in Australian pig production and
is commonly resistant to multiple antimicrobial agents (Smith
et al., 2016).
Salmonella enterica, subspecies enterica one of the primary
subspecies of Salmonella associated with foodborne disease and
a well-known zoonotic pathogen, is commonly carried by pigs
and other food-producing animals (Abraham et al., 2014b). High
rates of multidrug resistance have been found in Salmonella
iolates from food-producing animals in several countries. For
example, 54.5–55.6% of Salmonella spp. isolates from bovine
carcasses in Croatia and Spain (European Food Safety Authority
(EFSA), and European Centre for Disease Prevention and
Control (ECDC), 2017); 66% of Salmonella spp. isolates from
poultry and swine in Thailand (Van et al., 2012); and 41%
of turkey, 8.3% of chicken and 17% of cattle Salmonella spp.
isolates in the United States (Centers for Disease Control and
Prevention (CDC), U.S. Department of Agriculture(USDA), and
Food and Drug Administration (FDA), 2014) are multidrug-
resistant (MDR). A recent Australian study found a high
proportion (66.1%) of clinical Salmonella spp. isolates from
food-producing animals, the majority obtained from bovine
sources, were susceptible to all antimicrobials tested, including
to critically important antimicrobials (CIAs), namely extended-
spectrum cephalosporins (ESCs) and fluoroquinolones (FQs)
(Abraham et al., 2014a). This low rate of resistance among bovine
origin Salmonella spp. isolates was also confirmed in a study
of Salmonella carriage in healthy cattle at slaughter (Barlow
et al., 2015). However, ESC-resistant Salmonella spp. strains have
recently been isolated from Australian dairy cattle in Gippsland,
Victoria (Sparham et al., 2017). Although Australian pigs have
previously been considered to have low rates of Salmonella
spp. infection, since 2011 increasing numbers of clinical cases
have been reported (Hamilton et al., 2015). Despite this, there
have been no published studies on the estimated prevalence of
antimicrobial resistance (AMR) in Salmonella spp. isolated from
healthy Australian pigs at slaughter.
Antimicrobial agents are vital for the treatment and control
of many bacterial diseases in pig production (Smith et al.,
2016), but widespread use is often associated with the selection
of AMR (Smith et al., 2016). MDR pathogens in humans,
companion, and food-producing animals are a potential threat
to animal health through the loss of antibiotic effectiveness to
treat diseases and also to human health via direct cross-infection
or foodborne transmission of organisms such as Salmonella spp.
or indirectly through the transfer of mobile genetic elements,
such as plasmids, between bacteria (Jordan et al., 2009; Mukerji
et al., 2017). The reported use of antimicrobials and associated
resistance in food-producing animals differs throughout the
world. European AMR surveillance data show large differences
between countries in both their antimicrobial use and frequency
of AMR in key indicator bacteria (Österberg et al., 2016). For
example, in respective studies undertaken in Italy and Poland,
12% (n = 125) (Österberg et al., 2016) and 11.1% (n = 190)
(Wasyl et al., 2013) of E. coli isolated from the feces of
healthy pigs close to slaughter weight were resistant or non-
wild type to ciprofloxacin respectively. In contrast, similar studies
undertaken in Canada during 2013 and Sweden in 2015, reported
frequencies of resistance and non-wild type to ciprofloxacin of
2.4% (n = 171) and 2.5% (n = 200), respectively (Government
of Canada, 2015; Swedish Veterinary Antimicrobial Resistance
Monitoring (SVARM), 2015). In France, the frequency of
ciprofloxacin resistance in E. coli isolated from porcine colonic
contents at slaughter was 4.3% (n = 94). Interestingly, no
ciprofloxacin resistance was reported from isolates collected
during a contemporaneous study in Denmark (n = 52)
(Österberg et al., 2016).
Australia was recently ranked the 5th lowest user of
antimicrobials in livestock (mg/kg) in the world (O’Neill, 2015),
which may in part be due to its heavy reliance on extensive
grazing systems, but could also be related to other factors.
Antimicrobials approved in Australia for the treatment of
infections in pigs cover a broad range of classes and include
sulphonamide-trimethoprim combinations, tetracyclines, β-
lactams, and aminoglycosides (neomycin, apramycin, and
spectinomycin) (Smith et al., 2016). Other antimicrobials, such
as the ESC ceftiofur and the phenicol florfenicol, can be used
by Australian veterinarians “off label” for individual cases of
porcine colibacillosis as they are only approved for use for
respiratory infections in cattle (ceftiofur), and both cattle and
pigs (florfenicol) (Smith et al., 2016). In contrast to several
other countries, the use of CIAs in Australian livestock is highly
regulated (Smith et al., 2016; Mukerji et al., 2017). Australia
is the only country to implement legal measures that exclude
the use of FQs and gentamicin in food-producing animals
(Abraham et al., 2014a). Further, no product containing colistin
has been registered for use in Australian livestock for over 25
years (Australian Pesticides and Veterinary Medicine Authority
(APVMA), 2017). In addition, by international comparison,
the label constraints on the use of ESCs in Australian livestock
are strict, while the ESC cefquinome is not registered for use.
However, in a 2006 study, off label use of ceftiofur was reported
to have occurred on 25% of Australian piggeries (Jordan et al.,
2009).
Minimum inhibitory concentration (MIC) testing of
commensal bacteria from healthy animals is commonly used
to evaluate the occurrence of AMR in animal populations
and farms and is the basis for mandatory monitoring of food
production animals in the European Union (EU) (Österberg
et al., 2016). Importantly, commensal bacteria such as E. coli
can be reservoirs of plasmid-associated resistance genes
of public health significance (Trott, 2013). While proof
of concept national AMR surveys in the various livestock
sectors have commenced (Shaban et al., 2014), a number
of opportunistic surveys conducted in recent years have
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confirmed a low public health risk in the Australian food
animal sector in relation to resistance to CIAs, such as
FQs and ESCs (Abraham et al., 2012, 2014a, 2015; Barlow
et al., 2015). However, given the critical differences between
the antimicrobial use in the Australian pig industry and
elsewhere, and the lack of contemporary information on
the occurrence of resistance, the aim of this pilot study was
to investigate the occurrence of AMR among commensal
E. coli and Salmonella spp. isolated from cecal contents
of Australian finisher pigs at slaughter. The frequency of
isolates with MICs classified as non-susceptible based on
Clinical Laboratory Standards Institute (CLSI) and National
Antimicrobial Resistance Monitoring System (NARMS) clinical
breakpoints was determined. In addition, isolates with MICs
above the wild-type epidemiological cut off values (ECOFFs) for
CIAs were further characterized by whole genome sequencing
analysis.
MATERIALS AND METHODS
Sample Collection, Isolation, and
Identification
All cecal specimens were obtained using a systematic-random
sampling method from healthy pigs at slaughter originating
from 19 farms distributed throughout Australia between July
and December 2015. Abattoirs were identified based on their
eligibility criteria (e.g., export abattoirs processing finishing pigs
where a Department of Agriculture on-plant veterinarian was
present) and then randomly selected. The number of animals
sampled from each abattoir was proportional to the output of
that establishment, and calculated in advance. A systematic-
random method of sampling was used with samples collected
at regular intervals along the chain throughout the day. The
interval between collections of individual samples for each plant
was calculated (approx.) as a function of chain speed, daily
throughput and shift length. A total of 201 pigs were sampled
with one sample per pig obtained after slaughter and scalding
when the gastrointestinal tract was removed. Samples were stored
at 2–4◦C before being packed and shipped with samples arriving
at the primary laboratory within 24 h of collection.
A 10 g sample of fecal material was suspended in 7ml of 0.1%
sterile buffered peptone water (BPW) and thoroughly mixed,
before 1ml of the fecal mixture was extracted and centrifuged.
The homogenate was plated on to MacConkey agar (Oxoid,
Thermofisher Scientific) and incubated at 37◦C for 18–24 h.
Several lactose positive presumptive E. coli colonies were sub-
cultured onto sheep blood agar (SBA) (Oxoid, Thermofisher
Scientific) and incubated at 37◦C for 24 h. One colony identified
as E. coli using standard biochemical tests (Markey et al., 2013)
was used for further analysis. For Salmonella isolation, the
remaining fecal sample in BPW was incubated at 37◦C for
18–24 h. Following incubation 10ml of Rappaport-Vassiliadis
broth (Micromedia, Edwards) was inoculated with 0.1ml of the
incubated buffered peptone water and incubated at 42◦C for 18 h.
An aliquot was then streak plated onto Salmonella Brilliance agar
(Oxoid, Thermofisher Scientific) and XLD agar (Micromedia,
Edwards) to select for single colonies and incubated at 37◦C
for 24 h. Well isolated single colonies were sub-cultured onto
SBA and incubated at 37◦C for 24 h. These presumptive
Salmonella spp. isolates were then confirmed biochemically
(Markey et al., 2013), with one isolate per sample selected for
further analysis. The identity of each bacterial isolate to species
(E. coli and Salmonella spp.) level was confirmed using mass-
spectrometry (MALDI-TOF) prior to antimicrobial susceptibility
testing (AST).
Antimicrobial Susceptibility Testing
AST was performed by micro-broth dilution using commercially
prepared dryform panels (Sensititre CMV3AGNF, NARMS; Trek
Diagnostic Systems, Thermofisher Scientific). Inoculation and
incubation was carried out as per the manufacturer’s guidelines,
with quality control strains E. coli ATCC 35218, E. coli ATCC
25922, Enterococcus fecalis ATCC 29212, Staphylococcus aureus
ATCC 29213, and Pseudomonas aeruginosa ATCC 27853
used throughout the study. The antimicrobials tested were
ampicillin, amoxicillin/clavulanic acid, cefoxitin, ceftiofur,
ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin,
streptomycin, tetracycline and trimethoprim/sulfamethoxazole
and were selected based on consultation with industry and
their widespread use in international antimicrobial resistance
surveillance programmes (Shaban et al., 2014). MICs were
interpreted using CLSI VET01S (Clinical Laboratory Standard
Institute, 2015) guidelines or NARMS guidelines (Centers for
Disease Control and Prevention (CDC), U.S. Department of
Agriculture(USDA), and Food and Drug Administration (FDA),
2014) where no interpretative criteria were available (Table 1). In
addition, CLSI M100S (Clinical Laboratory Standards Institute,
2016) breakpoints were used where animal species specific
breakpoints were not available. Isolates with MICs above the
susceptible breakpoint (i.e., in the intermediate or resistant
category) were classified as non-susceptible (Clinical Laboratory
Standards Institute, 2011). Resistance profiles were generated,
with isolates classified as MDR if they showed non-susceptibility
to one antimicrobial agent in three or more antimicrobial
classes (Magiorakos et al., 2012). The European Committee on
Antimicrobial Susceptibility Testing (EUCAST) ECOFFs were
used to select isolates with an MIC value above the wild-type for
ESCs and FQs.
Whole Genome Sequencing
Whole genome sequencing was performed on eight isolates
that had an ECOFF value above the wild-type for either ESCs
or FQs, using Illumina MiSeq as described by Worthing et al.
(2017). Briefly, samples underwent library preparation using
the Nextera XT DNA library preparation kit according to the
manufacturer’s instructions, and sequencing was performed
on a MiSeq V3 2x300 flow cell. The Nullarbor pipeline v1.01
(https://github.com/tseemann/nullarbor) was used to assemble
the eight Illumina sequenced strains. The resulting FASTA
files were analyzed using the ResFinder, VirulenceFinder
and PlasmidFinder functions of the Centre for Genomic
Epidemiology database (http://www.genomicepidemiology.
org/).
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TABLE 1 | Breakpoints used for AST testing of E. coli and Salmonella spp. isolates.
Antimicrobial class Antimicrobial agent Range (µg/ml) ECOFFa CLSIb or NARMSc
E. coli Salmonella spp. S I R
Aminoglycosides Gentamicin 0.25–16 2 2 ≤4 8 ≥16
Streptomycin 2–64 16 16 ≤32 – > 32
β-lactam / β-lactam inhibitor
combinations
Amoxicillin-clavulanate 1–32 –d – ≤8 16 ≥32
Cephems Cefoxitin 0.5–32 8 8 ≤8 16 ≥32
Ceftiofur 0.12–8 1 2 ≤2 e 4 ≥8
Ceftriaxone 0.25–64 0.12 – ≤1 2 ≥4
Fluoroquinolones Ciprofloxacin (E. coli) 0.015–4 0.06 0.06 ≤1 2 ≥4
Ciprofloxacin (Salmonella spp.) 0.015–4 0.06 0.06 ≤0.06 0.12–0.5 ≥1
Folate pathway inhibitors Trimethoprim-sulfamethoxazole 0.12–4 1 1 ≤2 – ≥4
Penicillins Ampicillin 1–32 8 8 ≤8 16 ≥32
Phenicols Chloramphenicol 2–32 16 16 ≤8 16 ≥32
Tetracyclines Tetracycline 4–32 8 8 ≤4 8 ≥16
aEUCAST epidemiological cut-off values (µg/ml).
bCLSI VET01S, or M100S breakpoints (µg/ml), S = sensitive; I = intermediate; R = resistant.





E. coli was isolated from all porcine cecal samples collected
(n= 201). In contrast, Salmonella spp. were only recovered from




The 201 E. coli isolates showed the highest levels of non-
susceptibility to ampicillin (60.2%), tetracycline (68.2%),
chloramphenicol (47.8%) and trimethoprim/sulfamethoxazole
(34.3%) (Figure 1). By contrast, although the 69 Salmonella
spp. isolates also showed the highest levels of non-susceptibility
to ampicillin and tetracycline, these had a lower frequency
of occurrence (20.3 and 26.1%, respectively). Furthermore,
Salmonella spp. isolates had lower levels of non-susceptibility to
trimethoprim/sulfamethoxazole (11.6%) and chloramphenicol
(7.3%). Fifty-one percent of E. coli and 21.7% of Salmonella spp.
isolates were classified as MDR.
Low levels of non-susceptibility were observed among
isolates of both species to amoxicillin/clavulanate (E. coli 9.5%;
Salmonella spp. 2.9%) and gentamicin (E. coli 0.5%; Salmonella
spp. 2.9%). Overall, low levels of non-susceptibility were detected
to antimicrobials classified as critically important to human
health (ESCs and FQs). Ceftiofur non-susceptibility was not
observed for either E. coli or Salmonella spp. However, two
Salmonella spp. isolates (2.9%) were found to have MIC values
above the wild-type ECOFF (Table 2). Four E. coli isolates
(2.0%) had ciprofloxacin MICs above 0.25µg/ml, which is also
above the wild-type ECOFF (MIC > 0.06µg/ml). However,
only two of these isolates, both obtained from the same farm
(farm Q), had MICs above the CLSI resistant clinical breakpoint
(MICs of > 4µg/ml), despite no reported usage of FQs on
this farm according to the Australian Pork Industry Quality
Assurance Program (APIQ) audits. In addition, two E. coli
isolates (1.0%) had cefoxitin MICs above the wild-type ECOFF
andwere classified as non-susceptible on the basis of CLSI clinical
breakpoints. All isolates from farmQ (n= 12) were also classified
as MDR. One E. coli isolate (MIC above the cefoxitin wild-type
ECOFF) and one Salmonella spp. isolate (MIC above the ceftiofur
wild-type ECOFF) were isolated from the same farm (farm D).
All other isolates showing non-susceptibility to ESCs and/or
FQs were obtained from different farms [farms H, K, R, and X
(n = 1 for all farms)]. One of the Salmonella spp. isolates with
a MIC value above the wild-type ECOFF for ceftiofur showed
susceptibility to all other antimicrobials tested (farm H). The
other seven isolates of interest were classified as MDR.
The percentage of MDR E. coli isolates was further broken
down and analyzed on a per farm basis (Figure 2). Although the
sample size per farm is limited, there is sufficient evidence to
suggest there is a large variation between farms in the underlying
proportion of E. coli that are MDR. The Salmonella spp. were
unable to be analyzed by farm due to the lower number of
isolates obtained. As shown in Table 3 the most common MDR
profile was non-susceptibility to β-lactam/β-lactam inhibitor
combinations, phenicols, aminoglycosides, tetracyclines and
folate pathway inhibitors; followed by non-susceptibility to β-
lactam/β-lactam inhibitors, phenicols and tetracyclines.
Molecular Characterization
Eight isolates were selected for whole genome sequencing based
on having MICs at or above the ECOFF for CIAs. These
comprised the two E. coli isolates that were clinically resistant to
FQs from farm Q (ciprofloxacin MICs > 4µg/ml), two E. coli
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FIGURE 1 | Percentage of E. coli (n = 201) and Salmonella spp. (n = 69) isolates showing non-susceptibility to 11 selected antimicrobials. AMC, amoxicillin/clavulanic
acid; AMP, ampicillin; FOX, cefoxitin; CFT, ceftiofur; AXO, ceftriaxone; CHL, chloramphenicol; CIP, ciprofloxacin; GEN, gentamicin; STR, streptomycin; TET,
tetracycline; SXT, trimethoprim/sulfamethoxazole.
isolates with ciprofloxacin MICs of 0.25µg/ml and 0.5µg/ml,
two E. coli isolates with cefoxitin MICs of 32µg/ml, and two
Salmonella isolates with ceftiofur MICs of 2µg/ml (Table 4).
Four of the six E. coli isolates belonged to E. coli sequence type
(ST) 10, which belongs to phylogenetic group A and is commonly
isolated from a range of animal species as well as humans. All
E. coli ST10 isolates were classified as MDR and possessed at least
one β-lactamase gene, but no ESC resistance-associated genes
were identified in these isolates. The three ST10 isolates with the
highest ciprofloxacin MICs had similar amino acid substitutions
in the quinolone resistance-determining regions (QRDRs) of
DNA gyrase A subunit (GyrA) and topoisomerase IV A subunit
(ParC). The main substitutions of note were S83L and D87N
in GyrA and S80I in ParC. Although other point mutations
were identified in GyrB (A185G) and ParE (I136V), these are
not typically associated with quinolone resistance. Whilst it is
possible that additional mechanisms of FQ resistance, such as
overexpression of efflux pumps may be present in the two ST10
isolates with ciprofloxacin MICs > 4.0µg/ml, their genomes
were not interrogated further.
The remaining E. coli isolates belonged to a new sequence
type, designated ST7573, and ST4417 (Table 4). The isolate
belonging to ST7573 was the only isolate that contained a
plasmid-mediated quinolone resistance (PMQR) gene (qnrS1).
However, this isolate was still classified as ciprofloxacin-
susceptible according to CLSI guidelines, and did not possess any
identifiable chromosomally-encoded FQ resistance mechanisms.
Further, this isolate was MDR and contained the extraintestinal
pathogenic E. coli (ExPEC) virulence factor gene iss, which
encodes for increased serum survival, in addition to a range of
microcin-associated genes, the EAST-1 toxin (astA) and long
polar flagella genes (ipfA) (Table 4). However, this particular
combination of E. coli virulence genes does not classify the
ST7573 isolate as belonging to any particular E. coli pathotype.
The iss virulence associated gene was also identified in two
E. coli isolates belonging to ST10 together with gad, a glutamate
decarboxylase gene involved in acid tolerance. Apart from the
cellobiose utilization gene celB being identified in one ST10
isolate and the single ST4417 isolate, no other ExPEC-associated
virulence genes were identified in any of the isolates subjected to
whole genome sequence analysis.
The two Salmonella spp. isolates belonged to ST469 (serotype
Rissen), a commonly distributed serotype previously associated
with pig production, and ST515 (serotype Johannesburg).
Isolate sequences were deposited in Enterobase with the
accession numbers: traces-0GpondC, traces-0GQRdxI, traces-
0YZcnKW, traces-0ILjJIq, traces-0bhIgfw, and traces-0fwHIrT
(E. coli isolates 1, 2, 3, 4, 5, and 6 respectively) and
traces-0OMUTNy and traces-0LIahFC (Salmonella spp. isolates
1 and 2).
DISCUSSION
The main aims of this study were to investigate the occurrence
of AMR among E. coli and Salmonella spp. isolated from healthy
Australian finisher pigs at slaughter and further characterize any
isolates found to be non-susceptible to CIAs (ESCs and FQs)
using whole genome sequencing. The major findings from this
study are: (1) Low levels of non-susceptibility to CIAs were
detected among both E. coli and Salmonella spp. isolates; (2)
Of the eight isolates with MICs above the wild-type for either
ciprofloxacin, cefoxitin or ceftiofur, four E. coli isolates belonged
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TABLE 2 | MIC distribution frequency of E. coli (n = 201) and Salmonella spp. (n = 69) isolates.
aUnshaded areas indicate MIC range for each agent available on the Sensititre CMV3AGNF card. MICs > than highest concentration available are indicated in the shaded region.
Vertical blue lines indicate EUCAST ECOFF values; CLSI susceptible (green) and resistant (red) breakpoints; and NARMS breakpoints (red dashes).
to ST10 including two isolates that were clinically resistant
to ciprofloxacin and one Salmonella spp. isolate belonged to
the internationally distributed ST469 associated with serotype
Rissen; and (3) High frequencies of non-susceptibility were
observed to antimicrobial classes with a lower importance
rating (Australian Strategic and Technical Advisory Group
on AMR (ASTAG), 2015; Australian Veterinary Association,
2015) that are registered for use in pigs in Australia (i.e.,
tetracyclines, aminopenicillins and sulphonamide/trimethoprim
combinations).
Ceftiofur resistance was previously reported in porcine
commensal E. coli isolated from 1.8% of pooled fecal samples
from finisher pigs at Australian piggeries. However, none of
the isolates possessed plasmid-mediated AmpC or extended-
spectrum β-lactamases (ESBLs) (Smith et al., 2016). The first
detection of ESC resistance associated with ESBLs in E. coli
from Australian food-producing animals was reported in clinical
isolates in 2015. A national survey of clinical isolates from
diseased pigs obtained from veterinary diagnostic laboratories
identified three porcine E. coli isolates (2.6%) as resistant to
ceftiofur, with one isolate, identified as an ST774 strain, also
exhibiting resistance to ciprofloxacin (Abraham et al., 2015).
The frequency of ciprofloxacin non-susceptibility observed in
the present study was also low (1%) with two isolates from
farm Q both exhibiting ciprofloxacin MICs above the resistant
clinical breakpoint (indicating that FQ-R ST10 was the dominant
E. coli present in the gut of slaughter age pigs on this farm).
This is a significant finding as it indicates the presence of
resistance to FQs in commensal E. coli from Australian pigs
despite the absence of direct on farm selection pressure. This
correlates to data from a recent Danish Integrated Antimicrobial
Resistance Monitoring and Research Programme (DANMAP)
report where 1% of E. coli isolated from cecal samples randomly
collected from healthy pigs at slaughter were identified as being
ciprofloxacin non-wild-type (Høg et al., 2015). FQ resistance
has previously been strongly correlated with the quantity of
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antimicrobials used in the treatment of pigs (Barton, 2014), so
given the legal constraints on FQ use in Australian pigs it is
possible that these isolates did not develop FQ resistance on
farm and were likely introduced from an extraneous source.
One hypothesis is that they may have been introduced via
human carriers or wild birds, as suggested by Abraham and co-
workers (Abraham et al., 2015), but other potential sources of
transmission could also be considered such as feed, water, rodents
and insects. This highlights the need for emphasis of biosecurity
measures and their widespread application and extension to
FIGURE 2 | Point estimates and 95% confidence interval for the percent of
commensal E. coli colonies expressing MDR phenotype within each of 19
Australian pig herds.
non-animal sources of AMR transmission, such as in-contact
humans.
Resistance to ceftiofur in commensal bacteria (Salmonella and
E. coli) isolated from pigs was first reported in 2002 in south-east
Asia (Hanson et al., 2002). Other reports soon followed (Barton,
2014). A recent Australian regional survey of fecal samples from
22 Australian commercial pig farms found 5.2% of E. coli isolates
were resistant to ceftiofur (van Breda et al., 2018). The emergence
of some level of non-susceptibility to ceftiofur in Australian herds
is not unexpected, given previous reporting of “off-label” use in
individual pigs, which is assumed to be for the treatment of ETEC
infection (Jordan et al., 2009), raising concerns of the potential
for cross-transfer of ceftiofur non-susceptibility to humans via
the food chain. However, the results of the current Australia-wide
survey suggest that ceftiofur-resistant commensal E. coli are not
dominant coliforms in the gut of slaughter age pigs that are likely
to be isolated during AMR surveillance programs. Nevertheless,
the emergence and recent detection of ceftiofur-resistant E. coli
containing AmpC and ESBLs (Abraham et al., 2015; van Breda
et al., 2018) confirms that off-label use of ESCs should be more
critically evaluated by the Australian industry, as has recently
occurred in Denmark (Agersø and Aarestrup, 2013). The Danish
Agriculture and Food Council recommended a voluntary ban
on the use of ESCs in pigs following increased detection of
ESBL resistance genes in swine production facilities (Agersø and
Aarestrup, 2013). It is noted that FQs are registered for use in
food-producing animals in many European countries, such as
Denmark, although restrictions on their use were introduced by
the Danish Veterinary and Food Administration (DVFA) in 2002
(Høg et al., 2015).
Multilocus sequence type (ST10) is an extremely diverse
E. coli lineage found in many different host species, belonging
TABLE 3 | Resistant and MDR profiles with the highest frequency in E. coli (n = 201) and Salmonella spp. (n = 69).
Number of
antimicrobial classes
Total no. of isolates (%) Resistance pattern (no. of isolates)
E. coli Salmonella spp. E. coli Salmonella spp.
All susceptible 26 (12.94) 46 (66.67) 26 45
1 33 (16.42) 6 (8.70) TET (20) SXT (3)
TET (3)
2 40 (19.90) 2 (2.90) BLA-TET (18) AMG-BLA (1)
CHL-SXT (1)
3 36 (17.91) 11 (15.94) BLA-CHL-TET (13) AMG-BLA-TET (9)
4 40 (19.90) 1 (1.45) BLA-CHL-SXT-TET (11)
AMG-CHL-SXT-TET (11)
AMG-BLA-SXT-TET (1)
5 20 (9.95) 2 (2.90) AMG-BLA-CHL-SXT-TET (14) AMG-BLA-BLI-SXT-TET (1)
AMG-BLA-CHL-SXT-TET(1)
6 3 (1.49) 1 (1.45) AMG-BLA-BLI-CHL-SXT-TET (2) AMG-BLA-BLI-CHL-SXT-TET (1)
7 3 (1.49) 0 (0) AMG-BLA-BLI-CHL-2GC-SXT-
TET (2)
-
Non-MDR 99 (49.25) 54 (78.26) 99 54
MDR 102 (50.75) 15 (21.74) 102 15
Antimicrobial categories included: aminoglycosides, AMG (gentamicin, streptomycin); penicillin, BLA (ampicillin); β-lactam inhibitors, BLI (amoxicillin-clavulanate); phenicols, CHL
(chloramphenicol); 2nd generation cephalosporins, 2GC (cefoxitin); folate pathway inhibitors, SXT (trimethoprim/sulfamethoxazole); and tetracycline, TET.
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to phylogenetic group A (Fischer et al., 2017). It was the
most prevalent ST among the E. coli isolates submitted for
whole genome sequencing (four of six isolates; 66.67%) and was
overrepresented in a recent whole genome sequence analysis
of porcine commensal E. coli isolated from two piggeries in
Australia (Reid et al., 2017). ST10 is recognized as a potentially
zooanthroponotic commensal clonal lineage that has also been
identified as a cause of extraintestinal infections in humans in
both hospital and community settings in the Netherlands and
Canada. It has also been detected in poultry, wild birds, pigs and
retail chicken and pork meat (Abraham et al., 2015). Previous
studies have isolated an ESC-non-susceptible ST10 E. coli strain
from a calf with diarrhea in Australia (Abraham et al., 2015),
as well as dust and manure samples from piggeries in Germany
(Fischer et al., 2017). Carriage by European farmers has also been
previously reported (Fischer et al., 2017). However, its potential
contribution to the spread of AMR between humans and animals
is a very recent observation (Wang et al., 2016). Its frequent
association with ESBL production, and widespread detection
in humans, meat products and food animals, are important
epidemiological traits (Manges and Johnson, 2012). Although
the increased serum survival (iss) gene, recognized for its role
in ExPEC infections (Miajlovic and Smith, 2014), was identified
in half the porcine ST10 isolates obtained in the present study,
the isolates do not conform to the molecular definition of an
ExPEC strain as they do not contain ≥2 of the ExPEC associated
virulence genes papA and/or papC, sfa/focDE, afa/draBC, kpsM
II, and iutA (Guo et al., 2015).
In the absence of PMQR genes, mutational alterations in the
FQ target enzymes DNA topoisomerase II and topoisomerase
IV are the major mechanisms through which chromosomal
resistance occurs in Gram-negative bacteria (Gruger et al., 2004).
In isolates showing FQ non-susceptibility, such as the ST10
isolates identified in this study, DNA gyrase, the primary target
in Gram-negative bacteria, normally possesses GyrA subunit
substitutions at amino acid positions S83 and/or D87 and ParC
subunit substitutions at S80 and E84 (Gruger et al., 2004).
One of the most common mutations that results in high level
resistance to FQs alters S83 to either L or W, which can result
in an approximate 10-fold increase in MIC (Gruger et al., 2004).
All three of the most common mutation sites (S83, D87 and
S80) were present in the two FQ-resistant ST10 isolates (MICs
> 4µg/ml) and a single isolate above the wild-type MIC (MIC
0.5µg/ml) obtained in this study.
The isolate belonging to the new ST7573 contained the
ipfA virulence gene, which encodes an adhesin that plays an
integral role in attachment of enteropathogenic E. coli (EPEC)
to the gut wall and has been found to be prevalent in both
clinical and commensal E. coli isolated from human and bovine
hosts (Blum and Leitner, 2013). This gene was identified in
association with the iss serum survival gene and astA toxin
genes, together with genes encoding microcins and microcin
immunity. In a recent study by Blum and Leitner (2013), iss and
astA were the most prevalent virulence factor genes identified
in E. coli associated with bovine mastitis (Blum and Leitner,
2013). A recent whole genome sequence comparative analysis of
103 porcine commensal E. coli from two piggeries in Australia
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identified a greater array of extraintestinal E. coli virulence genes
in 14 ST10 isolates (Reid et al., 2017), but none would conform
to the strict definition of an ExPEC strain (Guo et al., 2015). It
is therefore difficult to infer if these genes are adaption genes
commonly found in commensal E. coli or true virulence genes
(Abraham et al., 2012).
Two Salmonella spp. isolates with MICs above the ceftiofur
ECOFF were further characterized by whole genome sequencing.
Interestingly, one of the isolates belonging to ST469, a sequence
type commonly associated with the Salmonella spp. serotype
Rissen. This serotype is commonly isolated from both humans
and pork production systems in different parts of the world,
notably Asia (Pornsukarom et al., 2015). The second ST515
(serotype Johannesburg) has been previously isolated from a mix
of environmental, human and livestock isolates from Nigeria, the
U.S.A and the U.K. and interestingly, from boneless camel meat
in Australia (http://enterobase.warwick.ac.uk).
In conclusion, this study has identified E. coli isolates with
MICs above the wild-type for ciprofloxacin that belong to diverse
host range clonal lineages, such as ST10, in Australian piggeries,
despite strict biosecurity and the absence of FQ selection pressure
(Abraham et al., 2015). Such strains may have been introduced
into the Australian piggery environment from an external
source, possibly via humans, migratory birds or other vectors.
Overall, however, the results of this study endorse the generally
conservative approach to the use of CIAs in the Australian
pig industry as only very low levels of non-susceptibility to
these drugs were detected among both E. coli and Salmonella
spp. isolates from healthy finisher pigs. This represents
a baseline for benchmarking in future AMR surveillance
programs.
AUTHOR CONTRIBUTIONS
AK performed experiments, data analysis, and drafted and
prepared the manuscript. JB performed experiments and
analyzed data. MO performed whole genome sequencing,
sequencing analysis, andwas involved inmanuscript preparation.
TL performed whole genome sequencing. SA, DJ, PM, CM,
and DT were involved in experimental design development and
manuscript preparation.
FUNDING
This study was funded by Australian Pork Limited and in part
by ARC Linkage project LP130100736. CAM is an Australian
Research Council (ARC) Future Fellow (FT170100006).
ACKNOWLEDGMENTS
The authors acknowledge the assistance and support of the
abattoirs and primary laboratories for providing the samples.
REFERENCES
Abraham, S., Chin, J., Brouwers, H. J., Zhang, R., and Chapman, T. A. (2012).
Molecular serogrouping of porcine enterotoxigenic Escherichia coli from
Australia. J. Microbiol. Methods 88, 73–76. doi: 10.1016/j.mimet.2011.10.016
Abraham, S., Groves, M. D., Trott, D. J., Chapman, T. A., Turner, B., Hornitzky,
M., et al. (2014a). Salmonella enterica isolated from infections in Australian
livestock remain susceptible to critical antimicrobials. Int. J. Antimicrob. Agents
43, 126–130. doi: 10.1016/j.ijantimicag.2013.10.014
Abraham, S., Jordan, D., Wong, H. S., Johnson, J. R., Toleman, M. A., Wakeham,
D. L., et al. (2015). First detection of extended-spectrum cephalosporin
and fluoroquinolone-resistant Escherichia coli in Australian food-producing
animals. J. Glob. Antimicrob. Resist. 3, 273–277. doi: 10.1016/j.jgar.2015.08.002
Abraham, S., Trott, D. J., Jordan, D., Gordon, D. M., Groves, M. D., Fairbrother,
J. M., et al. (2014b). Phylogenetic and molecular insights into the evolution of
multidrug-resistant porcine enterotoxigenic Escherichia coli in Australia. Int. J.
Antimicrob. Agents 44, 105–111. doi: 10.1016/j.ijantimicag.2014.04.011
Agersø, Y., and Aarestrup, F. M. (2013). Voluntary ban on cephalosporin
use in Danish pig production has effectively reduced extended-spectrum
cephalosporinase-producing Escherichia coli in slaughter pigs. J. Antimicrob.
Chemother. 68, 569–572. doi: 10.1093/jac/dks427
Australian Pesticides and VeterinaryMedicine Authority (APVMA) (2017). Public
Chemical Registration Information System. Available online at: https://portal.
apvma.gov.au/pubcris
Australian Strategic and Technical Advisory Group on AMR (ASTAG) (2015).
Importance Ratings and Summary of Antibacterial Uses in Humans in Australia.
Australian Veterinary Association (2015). Importance Ratings and Summary of
Antibacterial Uses in Humans in Australia (Canberra, ACT).
Barlow, R. S., McMillan, K. E., Duffy, L. L., Fegan, N., Jordan, D., and Mellor, G. E.
(2015). Prevalence and antimicrobial resistance of Salmonella and Escherichia
coli from Australian cattle populations at slaughter. J. Food Prot. 78, 912–920.
doi: 10.4315/0362-028X.JFP-14-476
Barton, M. (2014). Impact of antibiotic use in the swine industry. Curr. Opin.
Microbiol. 19, 9–15. doi: 10.1016/j.mib.2014.05.017
Blum, S. E., and Leitner, G. (2013). Genotyping and virulence factors
assessment of bovine mastitis Escherichia coli. Vet. Microbiol. 163, 305–312.
doi: 10.1016/j.vetmic.2012.12.037
Centers for Disease Control and Prevention (CDC), U.S. Department of
Agriculture(USDA), and Food and Drug Administration (FDA) (2014).
NARMS Integrated Report: The National Antimicrobial Resistance Monitoring
System: Enteric Bacteria. U.S. Food and Drug Administration.
Clinical and Laboratory Standards Institute (2011). Generation, Presentation, and
Application of Antimicrobial Susceptibility Test Data for Bacteria of Animal
Origin: A Report. CLSI Document VET05-R. Wayne, PA: CLSI.
Clinical and Laboratory Standard Institute (2015). Performance Standards for
Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from
Animals; Third Informational Supplement. CLSI Document VET01-S3. Wayne,
PA: CLSI.
Clinical and Laboratory Standards Institute (2016). Performance Standards for
Antimicrobial Susceptibility Testing; Twenty-Seventh Informational Supplement.
CLSI Document M100-S27. Wayne, PA: CLSI.
European Food Safety Authority (EFSA), and European Centre for Disease
Prevention and Control (ECDC) (2017). The European Union summary
report on antimicrobial resistance in zoonotic and indicator bacteria from
humans, animals and food in 2015. EFSA J. 15:4694. doi: 10.2903/j.efsa.
2017.4694
Fischer, J., Hille, K., Ruddat, I., Mellmann, A., Köck, R., and Kreienbrock, L. (2017).
Simultaneous occurrence of MRSA and ESBL-producing Enterobacteriaceae on
pig farms and in nasal and stool samples from farmers. Vet. Microbiol. 200,
107–113. doi: 10.1016/j.vetmic.2016.05.021
Government of Canada (2015) Canadian Integrated Program for Antimicrobial
Resistance Surveilance (CIPARS) 2013 Annual Report - Chapter 2 Antimicrobial
Resistance. Public Health Agency of Canada.
Gruger, T., Nitiss, J. L., Maxwell, A., Zechiedrich, E. L., Heisig, P., Seeber,
S., et al. (2004). A mutation in Escherichia coli DNA gyrase conferring
quinolone resistance results in sensitivity to drugs targeting eukaryotic
topoisomerase II. Antimicrob. Agents Chemother. 48, 4495–4504.
doi: 10.1128/AAC.48.12.4495-4504.2004
Frontiers in Microbiology | www.frontiersin.org 10 July 2018 | Volume 9 | Article 1207
Kidsley et al. AMR Surveillance in Australian Pigs
Guo, S., Wakeham, D., Brouwers, H. J., Cobbold, R. N., Abraham, S.,
Mollinger, J. L., et al. (2015). Human-associated fluoroquinolone-resistant
Escherichia coli clonal lineages, including ST354, isolated from canine feces
and extraintestinal infections in Australia. Microb. Infect. 17, 266–274.
doi: 10.1016/j.micinf.2014.12.016
Hamilton, D., Holds, G., Hogg, G., Valcanis, M., and Kiermeier, A. (2015).
“Longitudinal study of an Australian pig farm infected with monophasic
Salmonella Typhimurium-like PT193 (1,4,[5],12:i:-PT193) using MLVA,” in
Epidemiology and Control of Hazards in Pork Production Chain – SAFEPORK,
One Health Approach under a Concept of Farm to Fork (Porto), 127–130.
Hanson, R., Kaneene, J. B., Padungtod, P., Hirokawa, K., and Zeno, C. (2002).
Prevalence of Salmonella and E coli, and their resistance to antimicrobial agents,
in farming communities in northern Thailand. Southeast Asian J. Trop. Med.
Public Health 33(Suppl. 3.), 120–126.
Høg, B. B., Korsgaard, H., and Sönksen, U. W. (2015). DANMAP: Use of
Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria
from Food Animals, Food and Humans in Denmark. National Food Institute,
Technical University of Denmark.
Jordan, D., Chin, J. J., Fahy, V. A., Barton, M. D., Smith, M. G., and Trott, D. J.
(2009). Antimicrobial use in the Australian pig industry: results of a national
survey. Aust. Vet. J. 87, 222–229. doi: 10.1111/j.1751-0813.2009.00430.x
Mader, A., von Bronk, B., Ewald, B., Kesel, S., Schnetz, K., Frey, E., et al.
(2015). Amount of colicin release in Escherichia coli is regulated by
lysis gene expression of the colicin E2 operon. PLoS ONE 10:e0119124.
doi: 10.1371/journal.pone.0119124
Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E.,
Giske, C. G., et al. (2012). Multidrug-resistant, extensively drug-resistant
and pandrug-resistant bacteria: an international expert proposal for interim
standard definitions for acquired resistance.Clin.Microbiol. Infect. 18, 268–281.
doi: 10.1111/j.1469-0691.2011.03570.x
Manges, A. R., and Johnson, J. R. (2012). Food-borne origins of Escherichia
coli causing extraintestinal infections. Clin. Infect. Dis. 55, 712–719.
doi: 10.1093/cid/cis502
Markey, B., Leonard, F. C., Archambault, M., Cullinane, A., and Maguire, D.
(2013). Clinical Veterinary Microbiology. Edinburgh: Mosby-Elsevier.
Miajlovic, H., and Smith, S. G. (2014). Bacterial self-defence: how
Escherichia coli evades serum killing. FEMS Microbiol. Lett. 354, 1–9.
doi: 10.1111/1574-6968.12419
Mukerji, S., O’Dea, M., Barton, M., Kirkwood, R., Lee, T., and
Abraham, S. (2017). Development and transmission of antimicrobial
resistance among Gram-negative bacteria in animals and their
public health impact. Essays Biochem. 61, 23–35. doi: 10.1042/
EBC20160055
O’Neill, J. (2015). Antimicrobials in Agriculture and the Environment: Reducing
Unnecesssary Use and Waste. Review on Antimicrobial Resistance. London:




Österberg, J., Wingstrand, A., Nygaard Jensen, A., Kerouanton, A., Cibin, V.,
Barco, L., et al. (2016). Antibiotic resistance in Escherichia coli from pigs in
organic and conventional farming in four European countries. PLoS ONE
11:e0157049. doi: 10.1371/journal.pone.0157049
Poey, M. E., Azpiroz, M. F., and Laviña, M. (2006). Comparative analysis
of chromosome-encoded microcins. Antimicrob. Agents Chemother. 50,
1411–1418. doi: 10.1128/AAC.50.4.1411-1418.2006
Pornsukarom, S., Patchanee, P., Erdman, M., Cray, P. F., Wittum, T., Lee, J., et al.
(2015). Comparative phenotypic and genotypic analyses of Salmonella Rissen
that originated from food animals in Thailand and United States. Zoonoses
Public Health 62, 151–158. doi: 10.1111/zph.12144
Quinn, P., Markey, B., Leonard, F. C., FitzPatrick, E., Fanning, S., and Hartigan,
P. (2011). Veterinary Microbiology and Microbial Disease. Singapore: Wiley-
Blackwell.
Reid, C. J., Wyrsch, E. R., Roy Chowdhury, P., Zingali, T., Liu, M., Darling,
A. E., et al. (2017). Porcine commensal Escherichia coli: a reservoir for
class 1 integrons associated with IS26. Microbial Genomics 3:e000143.
doi: 10.1099/mgen.0.000143
Shaban, R. Z., Simon, G. I., Trott, D. J., Turnidge, J., and Jordan, D. (2014).
Sureveillance and Reporting of Antimicrobial Resistance and Antibiotic Usage
in Animals and Agriculture in Australia. Department of Agriculture.
Smith, M. G., Jordan, D., Gibson, J. S., Cobbold, R. N., Chapman, T. A., Abraham,
S., et al. (2016). Phenotypic and genotypic profiling of antimicrobial resistance
in enteric Escherichia coli communities isolated from finisher pigs in Australia.
Aust. Vet. J. 94, 371–376. doi: 10.1111/avj.12491
Sparham, S. J., Kwong, J. C., Valcanis, M., Easton, M., Trott, D. J., Seemann,
T., et al. (2017). Emergence of multidrug resistance in locally-acquired
human infections with Salmonella Typhimurium in Australia owing to a
new clade harbouring blaCTX-M-9. Int. J. Antimicrob. Agents 50, 101–105.
doi: 10.1016/j.ijantimicag.2017.02.014
Swedish Veterinary Antimicrobial Resistance Monitoring (SVARM) (2015).
Swedres-Svarm 2015 Consumption of Antibiotics and Occurence of Antibiotic
Resistance in Sweden. National Veterinay Institute.
Trott (2013). Beta-lactam resistance in Gram-negative pathogens isolated from
animals. Curr. Pharm. Des. 19, 239-249. doi: 10.2174/138161213804070339
van Breda, L. K., Dhungyel, O. P., and Ward, M. P. (2018). Antibiotic
resistant Escherichia coli in southeastern Australian pig herds and implications
for surveillance. Zoonoses Public Health 65, e1–e7. doi: 10.1111/zph.
12402
Van, T. T., Nguyen, H. N., Smooker, P. M., and Coloe, P. J. (2012). The antibiotic
resistance characteristics of non-typhoidal Salmonella enterica isolated from
food-producing animals, retail meat and humans in South East Asia. Int. J. Food
Microbiol. 154, 98–106. doi: 10.1016/j.ijfoodmicro.2011.12.032
Vassiliadis, G., Destoumieux-Garzón, D., Lombard, C., Rebuffat, S., and Peduzzi,
J. (2010). Isolation and characterization of two members of the siderophore-
microcin family, microcins M and H47. Antimicrob. Agents Chemother. 54,
288–297. doi: 10.1128/AAC.00744-09
Wang, J., Gibbons, J. F., McGrath, K., Bai, L., Li, F., Leonard, F. C., et al.
(2016). Molecular characterization of blaESBL-producing Escherichia coli
cultured from pig farms in Ireland. J. Antimicrob. Chemother. 71, 3062–3065.
doi: 10.1093/jac/dkw278
Wasyl, D., Hoszowski, A., Zajac, M., and Szulowski, K. (2013). Antimicrobial
resistance in commensal Escherichia coli isolated from animals at slaughter.
Front. Microbiol. 4:221. doi: 10.3389/fmicb.2013.00221
Worthing, K. A., Abraham, S., Pang, S., Coombs, G. W., Saputra, S., Jordan, D.,
et al. (2017). Molecular characterization of methicillin-resistant Staphylococcus
aureus isolated from Australian animals and veterinarians.Microb. Drug Resist.
24, 203–212. doi: 10.1089/mdr.2017.0032
Zimmerman, J. J., Karriker, L. A., Ramirez, A., Schwartz, K. J., and Stevenson, G.
W. (2012). Diseases of Swine. Iowa: Wiley-Blackwell.
Conflict of Interest Statement: DT has received research funding and
undertaken consultancies for Bayer, Zoetis, Merial, Virbac, Luoda Pharma,
Neoculi, and IRiccorgpharm. SA has received research funding from Zoetis and
Neoculi.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2018 Kidsley, Abraham, Bell, O’Dea, Laird, Jordan, Mitchell, McDevitt
and Trott. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 11 July 2018 | Volume 9 | Article 1207
